BioAdaptives, Inc. (BDPT)
OTCMKTS
· Delayed Price · Currency is USD
0.0091
-0.0009 (-9.00%)
Apr 29, 2026, 1:19 PM EST
BioAdaptives Revenue
In the year 2025, BioAdaptives had annual revenue of $18.28K with 44.27% growth. BioAdaptives had revenue of $10.43K in the quarter ending December 31, 2025.
Revenue
18.28K
Revenue Growth
+44.27%
P/S Ratio
5.98
Revenue / Employee
18.28K
Employees
1
Market Cap
109.28K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.28K | 5.61K | 44.27% |
| Dec 31, 2024 | 12.67K | -15.90K | -55.65% |
| Dec 31, 2023 | 28.57K | 11.39K | 66.31% |
| Dec 31, 2022 | 17.18K | -2.60K | -13.15% |
| Dec 31, 2021 | 19.78K | 3.45K | 21.12% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ayujoy Herbals | 70.87M |
| Twinlab Consolidated Holdings | 11.67M |
| Blue Star Foods | 4.24M |
| Altavoz Entertainment | 13.14K |
| NetBrands | 18.27K |
| Energy Today | 846.81K |
| Natur International | 686.72K |
| Dragon Capital Group | 21.91M |
BioAdaptives News
- 7 months ago - BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing - GlobeNewsWire
- 9 months ago - BioAdaptives' MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety - GlobeNewsWire
- 10 months ago - BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience - GlobeNewsWire
- 11 months ago - BioAdaptives Announces National Launch of Pawpa™ Regen - GlobeNewsWire
- 1 year ago - BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements - GlobeNewsWire
- 1 year ago - Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial - GlobeNewsWire
- 1 year ago - BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - GlobeNewsWire
- 1 year ago - BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors - GlobeNewsWire